RespireRx Pharmaceuticals (OTCQB:RSPI) CFO Jeff Margolis tells Proactive the Glen Rock, New Jersey-based group is advancing its slew of therapeutics throughout the clinical pipeline including a synthetic form of cannabinoid called dronabinol. Margolis says it aims to move to a Phase 3 clinical study to treat obstructive sleep apnea (OSA) with dronabinol. Meanwhile, Margolis says…